Prevalence and Specificity of Unexpected Antibody Using Antibody Screening Test Including Dia and Mia Cells.
- Author:
Nak Hyun SUNG
1
;
Tae Young JEON
;
Eun Yup LEE
;
Joo Seop CHUNG
;
Goon Jae CHO
;
Hyung Hoi KIM
Author Information
1. Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Unexpected antibody;
Anti-Dia;
Anti-Mia;
Korean population
- MeSH:
Antibodies;
Asian Continental Ancestry Group;
Humans;
Immunoglobulin G;
Korea;
Mass Screening*;
Phenotype;
Prevalence*;
Sensitivity and Specificity*
- From:The Korean Journal of Laboratory Medicine
2005;25(5):340-346
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The purpose of this study was to examine the prevalence and distribution of unexpected antibodies detected in the Korean population with race-specific RBC panel cells. In spite of a relatively high prevalence of Dia and Mia antigen phenotype in the Korean and Southeast Asian population, there has been little documented research on the prevalence and clinical significance of anti-Dia and anti-Mia in Korea. METHODS: We analyzed the results of 17, 664 antibody screening tests performed during the recent 30-month period from March 2001 to September 2003. Antibodies were screened and identified by using LISS/Coombs gel card with DiaMed-ID system (DiaMed AG, Cressier, Morat, Switzerland) including Dia and Mia panel cells. RESULTS: The prevalence of unexpected antibodies was 1.2% (214/17, 664); antibodies detected most frequently were anti-Rh (74 patients), followed by anti-Lewis (21 patients) and anti-Dia (15 patients). Out of 6, 345 patients, anti-Mia was detected in three patients (0.047%). Anti-Dia and anti-Mia had the specificity of IgG. Anti-Dia was thought as an immune-mediated antibody, whereas anti-Mia was considered as a mixed type with immune and natural antibodies. CONCLUSIONS: This study shows that anti-Dia and anti-Mia antibodies are detected frequently in the Korean population; hence, it seems that Dia and Mia panel cells should be incorporated into antibody screening panels in Korea for safe transfusion.
